Barclays lowered the firm’s price target on Intellia Therapeutics (NTLA) to $26 from $55 and keeps an Overweight rating on the shares following the Q4 report. The company highlighted clinical development progress and cost savings will support its cash runway into 2027, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics: Hold Rating Amid Long-Term Prospects and Strategic Restructuring
- Intellia Therapeutics Reports 2024 Financial Results and Progress
- Intellia Therapeutics’ Earnings Call: Progress and Challenges
- Intellia Therapeutics downgraded to Neutral from Overweight at JPMorgan
- Intellia Therapeutics price target raised to $14 from $12 at Citi